Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bone Cancer: early-phase trial registry
1 of 5 indexed Bone Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Bone Cancer: 5 US clinical trials tracked, 1 recruiting.
Bone Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Emerald Clinical, running 1 of these trials.
Enrollment posture brief
Registry condition bone-cancer
OPEN 1 | RECR 20% | LATE 0 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Bone Cancer lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bone Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bone Cancer is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Bone Cancer research.
Emerald Clinical accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Bone Cancer research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
The University of Texas Health Science Center at San Antonio
NCT03160274
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Dana-Farber Cancer Institute
NCT02880319
Osteosarcoma Maintenance Therapy With OST31-164
Emerald Clinical
NCT04974008
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT01553539
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT00019630
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Bone Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bone Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bone Cancer page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Bone Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Emerald Clinical sponsors the most Bone Cancer trials on record, review their full trial history before evaluating a specific study. See Emerald Clinical's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bone Cancer condition card totals 5 registered trials; most-linked intervention doxorubicin HCl liposome; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.